8-K
filed November 2, 2023, 7:59 PM ET
ticker CSTL
CIK 0001447362
earnings
confidence high
sentiment positive
materiality 0.85
Castle Biosciences Q3 revenue $61.5M (+66% YoY), raises FY2023 guidance to at least $200M
CASTLE BIOSCIENCES INC
2023-Q3 EPS reported
-$2.05
revenue$153,668,000
- Q3 revenue $61.5M, up 66% YoY; adjusted revenue $60.6M, up 63%.
- Total test reports 18,409 (+52% YoY); DecisionDx-Melanoma 8,559 (+16%), TissueCypher 2,829 (+310%).
- Net loss narrowed to $(6.9)M from $(20.2)M; adjusted EBITDA $6.6M vs $(9.6)M.
- Raised FY2023 revenue guidance to at least $200M from at least $180M.
- Operating cash flow positive $5.0M; cash $229.8M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
CASTLE BIOSCIENCES INC reported the third quarter ended September 30, 2023 results: revenue $61.5 million, net income $(6.9) million. Guidance raised.
- Period
- the third quarter ended September 30, 2023
- Revenue
- $61.5 million
- Net income
- $(6.9) million
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Revenues were $61.5 million, a 66% increase compared to $37.0 million during the same period in 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
CASTLE BIOSCIENCES INC reported the nine months ended September 30, 2023 results: revenue $153.7 million, net income $(54.9) million.
- Period
- the nine months ended September 30, 2023
- Revenue
- $153.7 million
- Net income
- $(54.9) million
- Result
- reported results
Exact text from the filing
Revenues were $153.7 million, a 56% increase compared to $98.7 million during the same period in 2022.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.